RT Journal Article
SR Electronic
T1 Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.06.10.447951
DO 10.1101/2021.06.10.447951
A1 Asghar Abdoli
A1 Reza Aalizadeh
A1 Hossein Aminianfar
A1 Zahra Kianmehr
A1 Ebrahim Azimi
A1 Nabbi Emamipour
A1 Hamidreza Jamshidi
A1 Mohammadreza Hosseinpour
A1 Mohammad Taqavian
A1 Hasan Jalili
YR 2021
UL http://biorxiv.org/content/early/2021/06/10/2021.06.10.447951.abstract
AB There is an urgent demand to manufacture an effective and safe vaccine to prevent SARS-CoV2 infection, which resulted in a global pandemic. In this study, we developed an inactivated whole-virus SARS-CoV-2 candidate vaccine named COVIran Barekat. Immunization at two different doses (3 µg or 5 µg per dose) elicited a high level of SARS-CoV-2 specific neutralizing antibodies in mice, rabbits, and non-human primates. The results show the safety profile in studied animals (include guinea pig, rabbit, mice, and monkeys). Rhesus macaques were immunized with the two-dose of 5 µg and 3 µg of the COVIran Barekat vaccine and showed highly efficient protection against 104 TCID50 of SARS-CoV-2 intratracheal challenge compared with the control group. These results highlight the COVIran Barekat vaccine as a potential candidate to induce a strong and potent immune response which may be a promising and feasible vaccine to protect against SARS-CoV2 infection.Competing Interest StatementThe authors have declared no competing interest.